Glycotope Reported Promising First-in-Man Data at American Society of Clinical Oncology 2013 for Its Glycooptimized Anti-EGFR Antibody CetuGEX™ to Treat Solid Tumors
6/5/2013 9:14:09 AM
More...
|
Glycotope Moves PankoMab™ Towards Phase-II Clinical Development
6/15/2012 9:04:11 AM
More...
|
Glycotope Moves FSH-GEX™ into Phase-II Clinical Development
6/8/2012 9:35:09 AM
More...
|
Glycotope Enrolls First Patients in Phase I Trial with TrasGEX(TM), a Glycooptimized HER2 Biobetter Antibody
9/19/2011 10:52:19 AM
More...
|
Glycotope Enrolls First Patients in Phase I Trial for FSH-GEX(TM)
5/18/2011 11:14:44 AM
More...
|
Glycotope Expands GMP Production Facility to 11 kg Antibody per Year
4/5/2011 9:01:59 AM
More...
|
Glycotope Receives Innovation Award Berlin Brandenburg 2010
12/14/2010 10:42:51 AM
More...
|
Glycotope Winner at STEP Award 2010
11/17/2010 2:41:22 PM
More...
|
Glycotope Presents Approved GlycoExpress-Technology at BIO-Europe 2010
11/12/2010 10:41:38 AM
More...
|
Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX(TM) and Enrolls First Patients in Clinical Trial
8/4/2010 11:27:35 AM
More...
|
|